Solmaz Rostami safarloo - Department of Animal Biology, Developmental Biology laboratory, School of Biology, University of Tehran, Tehran, Iran
Nafiseh Rahbarfam - Department of Animal Biology, Developmental Biology laboratory, School of Biology, University of Tehran, Tehran, Iran
Zeinab Dehghani Ghobadi - Department of Animal Biology, Developmental Biology laboratory, School of Biology, University of Tehran, Tehran, Iran
Hossein Ghamartaj - Department of Animal Biology, Developmental Biology laboratory, School of Biology, University of Tehran, Tehran, Iran

Ovarian cancer (OC) is frequently diagnosed at advanced stages due to its asymptomatic development. Although OC usually responds well to the first-line chemotherapy based on paclitaxel (PTX), the majority of patients develop recurrence and chemo-resistance. It is therefore critical to develop new approaches and treatment options to decrease the recurrence rate and to improve patient survival. Photodynamic therapy (PDT) involves the photochemical generation of cytotoxic reactive molecular species by non-toxic photosensitizers following exposure to non-harmful visible light, leading to localized cell death. Verteporfin (VP) is a photosensitizer used in photodynamic therapy for the treatment of age-related macular degeneration and neovascularization and has been tested for the treatment of several human cancers including breast cancer. This study aimed to investigate the effect of VP on the survival and migration of SKOV-۳ and OVCAR-۳ cell lines. For this purpose we have used MTT assay to assess the effect of VP on cells survival. Cells were treated with ۰, ۰.۲۵, ۰.۵, ۲.۵, ۵, and ۱۰ μM doses of Vin ۲۴, ۴۸ hours and followed by exposure to light for ۲۰ minutes. So MTT showed that the survival of cell significantly decreased with increasing concentration of VP and Duration of Treatment. (pvalu< ۰.۰۵) Moreover, a Scratch assay was used to evaluate the effect of VP on cell migration. We found that migration in the VP-treated group at a concentration of ۰.۵ μM was significantly reduced compared to the control. Based on our results we propose that VP may be considered as a potential drug for the treatment of ovarian cancer.

Verteporfin, migration, Cell survival